Skip to main content
IMDX
NASDAQ Life Sciences

Broadwood Partners, a 10% owner, significantly increases stake in Insight Molecular Diagnostics with over $2M in new purchases

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.84
Mkt Cap
$123.525M
52W Low
$2.33
52W High
$8.51
52W Position info
65% above low
Off High info
55% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

IMDX sits 65% above its 52-week low of $2.33 on elevated volume (2.2× avg).

Summary

Broadwood Partners, a major 10% owner of Insight Molecular Diagnostics, has reported an additional $2.03 million in open market stock purchases, continuing its accumulation trend.


Key Events · Ownership and Investor Activity · IMDX

  • Significant Insider Accumulation

    Broadwood Partners, L.P., along with Broadwood Capital Inc. and Neal C. Bradsher (President of Broadwood Capital), collectively a 10% owner, acquired an additional $2,032,251 worth of common stock through open market purchases.

  • Continued Investor Confidence

    These purchases, occurring between April 23 and April 27, 2026, follow a pattern of accumulation by Broadwood Partners, demonstrating continued confidence in Insight Molecular Diagnostics.

  • Substantial Stake Increase

    The transactions represent approximately 1.65% of the company's market capitalization, significantly increasing Broadwood Partners' total holdings to 12,684,884 shares.


Analysis · IMDX · Life Sciences

This Form 4 filing indicates a strong vote of confidence from Broadwood Partners, a significant 10% owner, and its principal, Neal C. Bradsher. The acquisition of over $2 million in additional shares, representing a material portion of the company's market capitalization, signals a bullish outlook. This latest round of purchases continues a recent trend of accumulation by Broadwood Partners, reinforcing their commitment to Insight Molecular Diagnostics. Investors should view this as a positive signal, especially given the company's recent progress in reducing net loss and advancing its FDA submission, as noted in its last 10-K.

At the time of this filing, IMDX was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.5M. The 52-week trading range was $2.33 to $8.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMDX - Latest Insights

IMDX
Jul 16, 2026, 3:22 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.63
Real-time Price: $4.73 info
Change: +$0.100 (+2%) info
Market Cap: $153.055M info
IMDX
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $4.73 info
Change: -$0.590 (-11%) info
Market Cap: $153.055M info
IMDX
Jun 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.32
Real-time Price: $4.73 info
Change: -$0.590 (-11%) info
Market Cap: $153.055M info
IMDX
May 13, 2026, 4:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.10
Real-time Price: $4.73 info
Change: -$0.370 (-7%) info
Market Cap: $153.055M info
IMDX
May 13, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.90
Real-time Price: $4.73 info
Change: -$0.170 (-3%) info
Market Cap: $153.055M info